Recent Updates
Recently added Catalysts

CP-547,632

Phase 2

Ovarian Neoplasms | Small molecule | Oncology |Pfizer, Inc.|Last Updated: Nov 7, 2006

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment29
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00074867Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube CancerPHASE2 COMPLETED 29 — — Oct 1, 2003Sep 1, 2004Nov 7, 20069 United States, Canada
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
At the completion of Stage 1 of the study, it did not meet the objective response criteria to proceed to Stage 2 of the trial.
Secondary Endpoints
Given the outcome of the primary objective, analysis of secondary objectives were not formalized.
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Interventions
NameTypeDescription
CP-547,632DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexFEMALE
Healthy VolunteersNo
Study Sites9

Inclusion Criteria: * Histologically proven epithelial ovarian cancer, primary peritoneal serous cancer, or fallopian tube cancerRecurrent or persistent elevated CA-125. * For the purpose of this study, elevated CA-125 is defined as a value of ≥40 U/ml on two separate consecutive determinations m...

Countries:United StatesCanada
Unlock Eligibility Criteria